Clinical trials
Completed Ovarian Neoplasms trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
124 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 4 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 8 |
| 2006 | 6 |
| 2007 | 1 |
| 2008 | 9 |
| 2009 | 5 |
| 2010 | 8 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 4 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 124 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 13 |
| Gynecologic Oncology Group | 8 |
| National Cancer Institute (NCI) | 8 |
| University Health Network, Toronto | 7 |
| NCIC Clinical Trials Group | 5 |
| pharmaand GmbH | 5 |
| Merck Sharp & Dohme LLC | 4 |
| Children's Oncology Group | 3 |
| Novartis Pharmaceuticals | 3 |
| Pfizer | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 124 |
| Fallopian Tube Neoplasms | 32 |
| Carcinoma, Ovarian Epithelial | 26 |
| Breast Neoplasms | 20 |
| Neoplasms | 17 |
| Endometrial Neoplasms | 14 |
| Pancreatic Neoplasms | 11 |
| Recurrence | 11 |
| Triple Negative Breast Neoplasms | 10 |
| Colorectal Neoplasms | 9 |
Trials
Showing 1 to 25 of 124. Each trial links to its page on Pharma Observatory.
24 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.